Table 1.
Patient characteristics
| Characteristic | No. | % |
|---|---|---|
| No. of patients | 79 | |
| Age, y | ||
| Median | 64 | |
| Range | 40-86 | |
| Gender | ||
| Male | 37 | |
| Female | 42 | |
| ISS stage | ||
| I | 27 | 34.2 |
| II | 31 | 39.2 |
| III | 21 | 26.6 |
| ECOG performance status | ||
| 0-1 | 75 | |
| ≥2 | 4 | |
| β2 microglobulin, mg/L | ||
| Median | 3.8 | |
| Range | 1.2-36.7 | |
| IgG | 36 | 45.6 |
| IgA | 16 | 32.9 |
| Light chain myeloma | 18 | 22.8 |
| Oligosecretory myeloma | 9 | 11.4 |
| FISH-defined cytogenetic risk groups | ||
| High risk: t(4;14), t(14;16), del17p, 1q21 | 30 | 43.5* |
| Standard risk: all others | 39 | 56.5* |
| Prior treatment lines | ||
| Median | 2 | |
| Range | 1-6 | |
| Prior exposure to bortezomib | 50 | 63.3 |
| Prior exposure to lenalidomide | 42 | 53.2 |
| Prior exposure to both bortezomib and lenalidomide | 29 | 36.7 |
ECOG, Eastern Cooperative Oncology Group; IgG, immunoglobulin G.
*
Cytogenetic results available from 60 patients: t (4;14), 10; t(14;16), 1; del17p, 9; 1q21, 22 (20 patients had ≥2 aberrations).